Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 8Hodgkin Disease 4Lymphoma, Non-Hodgkin 2Recurrence 1Radiation Injuries 1Neurotoxicity Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1HIV Infections 1

Interventions

Taxes 2Paclitaxel 2Oxaliplatin 2Magnesium Sulfate 2Carboplatin 2Calcium Gluconate 2haloperidol decanoate 1glutamic acid diethyl ester 1axicabtagene ciloleucel 1Vitamin E 1Vincristine 1Thalidomide 1Surveys and Questionnaires 1Rituximab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiosurgery 1Procarbazine 1Peripheral Blood Stem Cell Transplantation 1Pain Management 1Modafinil 1Methotrexate 1Memantine 1Melphalan 1Lorazepam 1Leucovorin 1Lamotrigine 1Ketamine 1Interleukin 1 Receptor Antagonist Protein 1In Situ Hybridization, Fluorescence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurotoxicity Syndromes × Procarbazine × Clear all
NCT01399372 2023-07-20

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Radiation Therapy Oncology Group

Phase 2 Completed
91 enrolled 17 charts
Lymphoid

Lymphoma, Radiation Injuries, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡